Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Pauline Verdijk, Nynke Y Rots & Wilfried AM Bakker. (2011) Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Review of Vaccines 10:5, pages 635-644.
Read now
Read now
Amit A. Lugade, Suresh Kalathil, Jonathan L. Heald & Yasmin Thanavala. (2010) Transgenic Plant-Based Oral Vaccines. Immunological Investigations 39:4-5, pages 468-482.
Read now
Read now
Articles from other publishers (51)
Saman Raza. 2023. COVID-19: Origin, Impact and Management, Part 1. COVID-19: Origin, Impact and Management, Part 1
139
155
.
钦 王. (2023) Research Progress in Clinical Pharmacology of Pulsatilla saponins in Cancer. Advances in Clinical Medicine 13:08, pages 13067-13073.
Crossref
Crossref
Sunny Kumar, Malini Basu, Pratyasha Ghosh, Aafreen Ansari & Mrinal K. Ghosh. (2022) COVID‐19: Clinical status of vaccine development to date. British Journal of Clinical Pharmacology 89:1, pages 114-149.
Crossref
Crossref
Emmanuel J. Vidor & John F. Modlin. 2023. Plotkin's Vaccines. Plotkin's Vaccines
890
913.e14
.
Lester M. Shulman. 2023. Infectious Diseases. Infectious Diseases
251
323
.
K. Savina, Rakhy Sreekumar, V. K. Soonu & E. J. Variyar. (2022) Various vaccine platforms in the field of COVID-19. Beni-Suef University Journal of Basic and Applied Sciences 11:1.
Crossref
Crossref
Erin M. Euliano, Alexandros A. Sklavounos, Aaron R. Wheeler & Kevin J. McHugh. (2022) Translating diagnostics and drug delivery technologies to low-resource settings. Science Translational Medicine 14:666.
Crossref
Crossref
Grażyna Łaska, Magdalena Maciejewska-Turska, Elwira Sieniawska, Łukasz Świątek, David S. Pasco & Premalatha Balachandran. (2021) Extracts from Pulsatilla patens target cancer-related signaling pathways in HeLa cells. Scientific Reports 11:1.
Crossref
Crossref
Wagner Gouvêa dos Santos. (2021) Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomedicine & Pharmacotherapy 136, pages 111272.
Crossref
Crossref
Vasilica Ungureanu. (2021) The immune response in bacterial and viral infectious diseases. Medic.ro 3:141, pages 20.
Crossref
Crossref
Diana Kouiavskaia, Rama Devudu Puligedda, Scott K. Dessain & Konstantin Chumakov. (2020) Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines. Journal of Virological Methods 276, pages 113785.
Crossref
Crossref
Lester M. Shulman. 2020. Encyclopedia of Sustainability Science and Technology. Encyclopedia of Sustainability Science and Technology
1
73
.
K. Chumakov & A. A. Ishmukhametov. (2018) Polio Vaccines: Present and Future. Epidemiology and Vaccine Prevention 17:3, pages 4-18.
Crossref
Crossref
Ying Wan, John M. Hickey, Christopher Bird, Katey Witham, Paul Fahey, Angus Forster, Sangeeta B. Joshi & David B. Volkin. (2018) Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the Nanopatch™ Microprojection Array. Journal of Pharmaceutical Sciences 107:6, pages 1540-1551.
Crossref
Crossref
Emmanuel Vidor. 2018. Plotkin's Vaccines. Plotkin's Vaccines
841
865.e10
.
Radboud J Duintjer Tebbens & Kimberly M Thompson. (2016) The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiology 11:12, pages 1549-1561.
Crossref
Crossref
Hiromasa Okayasu, Carolyn Sein, Ahd Hamidi, Wilfried A.M. Bakker & Roland W. Sutter. (2016) Development of inactivated poliovirus vaccine from Sabin strains: A progress report. Biologicals 44:6, pages 581-587.
Crossref
Crossref
Stephany Y. Tzeng, Rohiverth Guarecuco, Kevin J. McHugh, Sviatlana Rose, Evan M. Rosenberg, Yingying Zeng, Robert Langer & Ana Jaklenec. (2016) Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release. Journal of Controlled Release 233, pages 101-113.
Crossref
Crossref
José Elías García-Sánchez, Enrique García-Sánchez, Enrique García-Merino & María José Fresnadillo-Martínez. (2015) La polio, el largo camino hacia el final de la partida. Enfermedades Infecciosas y Microbiología Clínica 33:10, pages e69-e78.
Crossref
Crossref
Thomas Hagan, Helder I. Nakaya, Shankar Subramaniam & Bali Pulendran. (2015) Systems vaccinology: Enabling rational vaccine design with systems biological approaches. Vaccine 33:40, pages 5294-5301.
Crossref
Crossref
Yvonne E. Thomassen & Wilfried A.M. Bakker. (2015) sIPV process development for costs reduction. Vaccine 33:35, pages 4307-4312.
Crossref
Crossref
M. Saqib, S. J. Wylie & M. G. K. Jones. (2015)
Serendipitous identification of a new
Iflavirus
-like virus infecting tomato and its subsequent characterization
. Plant Pathology 64:3, pages 519-527.
Crossref
Crossref
AishaAhmed Abubakar, AbdulrazaqA Gobir, MohammedS Ibrahim, PatrickM Nguku, MaryamB Akor-Dewu & FatimaL Chiroma. (2015) Assessment of oral polio vaccine coverage in the Nigeria demographic and health surveys 1990, 1999, 2003, and 2008. Sub-Saharan African Journal of Medicine 2:4, pages 175.
Crossref
Crossref
Carlo Amorin Daep, Jorge L. Muñoz-Jordán & Eliseo Alberto Eugenin. (2014) Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus. Journal of NeuroVirology 20:6, pages 539-560.
Crossref
Crossref
S. Chandir, K. U. Ahamed, A. H. Baqui, R. W. Sutter, H. Okayasu, M. A. Pallansch, M. S. Oberste, L. H. Moulton & N. A. Halsey. (2014) Effect of Buffer on the Immune Response to Trivalent Oral Poliovirus Vaccine in Bangladesh: A Community Based Randomized Controlled Trial. Journal of Infectious Diseases 210:suppl 1, pages S390-S397.
Crossref
Crossref
Heleen Kraan, Paul van Herpen, Gideon Kersten & Jean-Pierre Amorij. (2014) Development of Thermostable Lyophilized Inactivated Polio Vaccine. Pharmaceutical Research 31:10, pages 2618-2629.
Crossref
Crossref
Jan Felix DrexlerGilda GrardAlexander N. LukashevLiubov I. KozlovskayaSindy BöttcherGökhan UsluJohan ReimerinkAnatoly P. GmylRaphaël Taty-Taty, Sonia Etenna Lekana-DoukiDieudonné NkogheAnna M. Eis-HübingerSabine DiedrichMarion KoopmansEric M. Leroy & Christian Drosten. (2014) Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proceedings of the National Academy of Sciences 111:35, pages 12889-12894.
Crossref
Crossref
Benjamin P. Steil, Patricia Jorquera, Janny Westdijk, Wilfried A.M. Bakker, Robert E. Johnston & Mario Barro. (2014) A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine 32:5, pages 558-563.
Crossref
Crossref
Konstantin Chumakov. 2014. Novel Technologies for Vaccine Development. Novel Technologies for Vaccine Development
87
112
.
Pauline Verdijk, Nynke Y. Rots, Monique G.C.T. van Oijen, M. Steven Oberste, Claire J. Boog, Hiromasa Okayasu, Roland W. Sutter & Wilfried A.M. Bakker. (2013) Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: A phase I trial in healthy adults. Vaccine 31:47, pages 5531-5536.
Crossref
Crossref
Marian Wiegand, Gianni Gori-Savellini, Barbara Martorelli, Sascha Bossow, Wolfgang J. Neubert & Maria Grazia Cusi. (2013) Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector. Vaccine 31:37, pages 3888-3893.
Crossref
Crossref
P. Bellot, P. Tiels, V. Melkebeek, B. Devriendt, B.M. Goddeeris & E. Cox. (2013) Maltose-binding protein is a potential carrier for oral immunizations. Veterinary Immunology and Immunopathology 152:1-2, pages 101-108.
Crossref
Crossref
Roland W. Sutter, Olen M. Kew, Stephen L. Cochi & R. Bruce Aylward. 2013. Vaccines. Vaccines
598
645
.
Emmanuel Vidor & Stanley A. Plotkin. 2013. Vaccines. Vaccines
573
597
.
Lester M. Shulman. 2013. Infectious Diseases. Infectious Diseases
237
308
.
Ahd HamidiWilfried AM Bakker. (2012) Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains. Pharmaceutical Patent Analyst 1:5, pages 589-599.
Crossref
Crossref
Amit A. Lugade, Kalathil Suresh & Yasmin Thanavala. 2012. Vaccinology. Vaccinology
336
347
.
Gabriel I. Parra, Karin Bok, Ross Taylor, Joel R. Haynes, Stanislav V. Sosnovtsev, Charles Richardson & Kim Y. Green. (2012) Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 30:24, pages 3580-3586.
Crossref
Crossref
T. N. Dhole & Vikas Mishra. (2012) Polio Eradication in India. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences 82:1, pages 123-133.
Crossref
Crossref
Maria Trovato. (2012) Delivery strategies for novel vaccine formulations. World Journal of Virology 1:1, pages 4.
Crossref
Crossref
Holger Loessner, Astrid Schwantes, Matthias Hamdorf, Uliana Komor, Sara Leschner & Siegfried Weiss. 2012. Development of Novel Vaccines. Development of Novel Vaccines
87
124
.
Lester M. Shulman. 2012. Encyclopedia of Sustainability Science and Technology. Encyclopedia of Sustainability Science and Technology
8123
8173
.
Jiwon Hwang, Laura Winkler & Robert F. Kalejta. (2011) Ubiquitin-independent proteasomal degradation during oncogenic viral infections. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1816:2, pages 147-157.
Crossref
Crossref
Aurélie Girard, Wilfried Saron, Louis-Philippe Bergeron-Sandoval, Fathey Sarhan & Denis Archambault. (2011) Flagellin produced in plants is a potent adjuvant for oral immunization. Vaccine 29:38, pages 6695-6703.
Crossref
Crossref
Wilfried A.M. Bakker, Yvonne E. Thomassen, Aart G. van’t Oever, Janny Westdijk, Monique G.C.T. van Oijen, Lars C. Sundermann, Peter van’t Veld, Eelco Sleeman, Fred W. van Nimwegen, Ahd Hamidi, Gideon F.A. Kersten, Nico van den Heuvel, Jan T. Hendriks & Leo A. van der Pol. (2011) Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 29:41, pages 7188-7196.
Crossref
Crossref
Lester M. Shulman, Danit Sofer, Yossi Manor, Ella Mendelson, Jean Balanant, Anna Laura Salvati, Francis Delpeyroux & Lucia Fiore. (2011) Antiviral Activity of 3(2H)- and 6-Chloro-3(2H)-Isoflavenes against Highly Diverged, Neurovirulent Vaccine-Derived, Type2 Poliovirus Sewage Isolates. PLoS ONE 6:5, pages e18360.
Crossref
Crossref
Jean-Jacques Kuss. (2011) L'Initiative Mondiale pour l'Éradication de la Poliomyélite : un long chemin semé d'embûches. Santé Publique Vol. 23:1, pages 55-60.
Crossref
Crossref
Zhaochun Chen, Konstantin Chumakov, Eugenia Dragunsky, Diana Kouiavskaia, Michelle Makiya, Alexander Neverov, Gennady Rezapkin, Andrew Sebrell & Robert Purcell. (2011) Chimpanzee-Human Monoclonal Antibodies for Treatment of Chronic Poliovirus Excretors and Emergency Postexposure Prophylaxis. Journal of Virology 85:9, pages 4354-4362.
Crossref
Crossref
Susan L. Baldwin, Christopher B. Fox, Mark A. Pallansch, Rhea N. Coler, Steven G. Reed & Martin Friede. (2011) Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 29:4, pages 644-649.
Crossref
Crossref
Gert Zimmer. (2010) RNA Replicons - A New Approach for Influenza Virus Immunoprophylaxis. Viruses 2:2, pages 413-434.
Crossref
Crossref
Stanley A. Plotkin. (2009) Vaccines: the Fourth Century. Clinical and Vaccine Immunology 16:12, pages 1709-1719.
Crossref
Crossref